Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) and keeping the price target at $81.00.
Andrew Fein’s rating is based on the promising results from Arvinas Holding Company’s recent clinical trials and the potential market impact of their therapeutic developments. The Phase 3 VERITAC-2 study results showed significant efficacy of vepdeg in ESR1 mutant patients, which supports the mechanism of action of ER Protacs and oral SERDs. This suggests a strong potential for regulatory approval and market adoption, particularly in the ESR1 mutant patient population.
Furthermore, the preliminary data from the Phase 1b TACTIVE-U trial at the San Antonio Breast Cancer Symposium highlighted the safety and efficacy of vepdeg when combined with abemaciclib, showing a high clinical benefit rate in heavily pretreated patients. The combination therapy’s potential to enhance market penetration, along with the manageable safety profile, indicates a promising future for Arvinas’ products. These factors, combined with a robust valuation model, underpin Fein’s Buy rating and the price target of $81.
In another report released on February 27, Barclays also maintained a Buy rating on the stock with a $32.00 price target.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARVN in relation to earlier this year.